Community exercise program after procedures to restore blood flow in peripheral artery disease
Tests added community exercise therapy in people with peripheral artery disease having revascularization.
Key facts
- Who runs it
- University of Minnesota
- Where
- Minneapolis, United StatesSee the site
- Trial code
- Registry title
- Community-based Exercise Following Revascularization for PAD
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 8 Apr 2022
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CB-SET
- Revascularization
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with peripheral artery disease (narrowed leg arteries) who are having a procedure to restore blood flow (revascularization). It tests whether a community-based exercise program adds benefit.
- Age
- 40 Years to 90 Years
- Sex
- All sexes can join.
- Disease stage
- Peripheral artery disease, focal and/or diffuse, in the aorto-iliac and/or femoral-popliteal arteries of at least one leg. People having the procedure on both legs can also join. People with critical limb ischemia (pain at rest, ulcers or gangrene in the legs) cannot join.
- Earlier treatment
- People must be receiving revascularization. People treated with pentoxifylline or cilostazol for claudication in the 4 weeks before screening cannot join; they can be reconsidered after a 1-month break.
- Biomarker or test result
- Glycated hemoglobin must not be above 12% (108 mmol/mol).
Main reasons for not taking part
- Leg amputation that interferes with walking on a treadmill
- PAD not caused by atherosclerosis (for example fibromuscular dysplasia, irradiation, endofibrosis)
- Heart attack, stroke or TIA within 3 months, or heart bypass or major surgery within 6 months before screening
- Uncontrolled high blood pressure (≥180 systolic or ≥100 diastolic) or walking limited mainly by COPD, angina or heart failure
- Unable to speak English
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients receiving Revascularization for aorto-iliac and/or femoral-popliteal disease in at least one limb
- Patients with focal and/or diffuse peripheral artery disease
- Bilateral Revascularization patients will also be included
- Ability to participate in an exercise program
Who cannot take part
- PAD of non-atherosclerotic nature (e.g., fibromuscular dysplasia, irradiation, endofibrosis)
- Coronary artery bypass grafts or major surgical procedures within 6 months prior to screening
- Individuals who have had a myocardial infarction within 3 months prior to screening
- Individuals who have had a transient ischemic attack or stroke 3 months prior to screening
- Treatment with pentoxifylline or cilostazol for the treatment of claudication 4 weeks prior to screening. Patients can be reconsidered for study inclusion following a 1-month washout period
- Individuals whose walking exercise is primarily limited by symptoms of chronic obstructive pulmonary disease, angina, or heart failure
- Individuals with uncontrolled hypertension (≥180 systolic or ≥100 diastolic resting blood pressure) during screening
- Other clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurological, psychiatric, immunological, gastrointestinal, hematological, or metabolic disease that is, in the opinion of the study team, not stabilized or may otherwise confound the results of the study
- Poorly controlled diabetes defined as glycated hemoglobin >12%
- Lower extremity amputation(s) which interfere(s) with walking on the treadmill
- Individuals with critical limb ischemia defined by ischemic rest pain or ischemic ulcers/gangrene on the lower extremities
- Abnormal results of blood work not conducive to safely participate in an exercise trial (e.g., anemic, electrolyte abnormalities)
- Inability to speak English
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 90 years old?
Where in United States
- University of MinnesotaMinneapolis, United StatesContact: Ryan Mays, PhD, MPH, MSTaking people
About the trial
What the trial wants to find out
The primary goal of this clinical trial is to evaluate whether a community-based structured exercise therapy (CB-SET) intervention, which could be accessible and easily disseminated, adds benefit to peripheral artery disease (PAD) patients undergoing revascularization (REVASC) to improve their function and cardiovascular health.
The 2 groups in the trial
- CB-SET TreatmentTreatment being tested
Participants randomized to this group will receive a community-based structured exercise therapy (CB-SET) along with the standard of care (revascularization)
Treatment: CB-SET and Revascularization
- ControlExisting treatment, for comparison
Participants randomized to this group will receive standard of care (revascularization)
Treatment: Revascularization
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Community-based Exercise to Improve Physical Functioning and Cardiovascular Health Following Revascularization for Peripheral Artery Disease
- Plain-language title
- Community exercise program after procedures to restore blood flow in peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT04252950, who can take part
- Record updated
- 9 September 2026